| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 2,149 | 2,954 | 421 | 3,336 |
| Gain on fixed asset disposal | - | - | - | 97 |
| General and administrative | 4,939 | 3,679 | 4,173 | 2,867 |
| Research and development | 4,754 | 7,910 | 8,547 | 9,381 |
| Loss (gain) on fixed asset disposal | -51 | - | - | - |
| Total operating expenses | 9,744 | 11,589 | 12,720 | 12,151 |
| Loss from operations | -7,595 | -8,635 | -12,299 | -8,815 |
| Interest income | 222 | 198 | 170 | 343 |
| Interest expense | -75 | -45 | -128 | -188 |
| Total other income, net | 147 | 153 | 42 | 155 |
| Net loss | -7,448 | -8,482 | -12,257 | -8,660 |
| Unrealized gain from available-for-sale securities | 1 | - | - | - |
| Comprehensive loss | -7,447 | -8,482 | -12,257 | -8,660 |
| Net loss per common share, basic | -0.07 | -0.09 | -0.17 | -0.17 |
| Net loss per common share, diluted | -0.07 | -0.09 | -0.17 | -0.17 |
| Weighted average common shares outstanding, basic | 100,869,349 | 95,459,401 | 74,254,700 | 51,229,701 |
| Weighted average common shares outstanding, diluted | 100,869,349 | 95,459,401 | 74,254,700 | 51,229,701 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)